Recent Progress in DNA Damage Response-Targeting PROTAC Degraders.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Defects in DNA damage response (DDR) are fundamental to cancer development, leading to mutations that create cancer-specific vulnerabilities.
• Synthetic lethality therapies exploit these vulnerabilities, with small molecule DDR inhibitors showing clinical success.
• Tumor microenvironment mutations can reduce the efficacy of conventional DDR inhibitors.

Purpose of the Study:

• To review recent advancements in DDR-targeting PROTAC degraders for cancer therapy.
• To summarize the biological roles of various DDR targets.
• To discuss challenges and future prospects for DDR-targeting PROTAC degraders.

Main Methods:

• Literature review of recent progress in DDR-targeting PROTAC technology.
• Compilation of information on the biological functions of key DDR targets.
• Analysis of current challenges and future directions in the field.

Main Results:

• PROTAC technology represents a novel strategy for modulating DDR pathways.
• Understanding DDR target biology is crucial for designing effective degraders.
• PROTACs offer potential to overcome resistance mechanisms associated with small molecule inhibitors.

Conclusions:

• DDR-targeting PROTAC degraders are an emerging and promising therapeutic strategy in oncology.
• Further research is needed to address challenges and optimize PROTAC-based cancer therapies.
• PROTACs hold potential for improved efficacy and overcoming resistance in cancer treatment.